4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,630,220 | -22.9% | 363,725 | +9.4% | 0.00% | 0.0% |
| Q2 2023 | $6,005,871 | +27.3% | 332,367 | +21.1% | 0.00% | 0.0% |
| Q1 2023 | $4,717,434 | -22.7% | 274,429 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $6,103,774 | +174.5% | 274,821 | -0.7% | 0.00% | 0.0% |
| Q3 2022 | $2,224,000 | +16.1% | 276,680 | +0.9% | 0.00% | – |
| Q2 2022 | $1,915,000 | -51.1% | 274,331 | +5.8% | 0.00% | -100.0% |
| Q1 2022 | $3,920,000 | -29.8% | 259,280 | +1.9% | 0.00% | 0.0% |
| Q4 2021 | $5,581,000 | +9.0% | 254,372 | +34.0% | 0.00% | 0.0% |
| Q3 2021 | $5,119,000 | +115.6% | 189,825 | +92.7% | 0.00% | – |
| Q2 2021 | $2,374,000 | -37.2% | 98,528 | +13.1% | 0.00% | -100.0% |
| Q1 2021 | $3,780,000 | – | 87,143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |